topic

805 Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours
Mark Lythgoe, Justin Stebbing, Emily Pickford, Axel Glasmacher, Marsilio Adriani, Gayle Fyvie, Adam Frampton, Alex Stevenson, Jonathan Krell

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A481-A482; DOI: 10.1136/jitc-2020-SITC2020.0805
806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer
Luis Manso, Patricia Villagrasa, Nuria Chic, Begoña Bermejo, Juan Cejalvo, Yann Izarzugaza, Blanca Cantos, Salvador Blanch, Mireia Margeli, Jose Alonso, Alejandro Martínez, Rafael Villanueva, Juan Guerra, Raquel Andrés, Pilar Zamora, Esteban Nogales, Manel Juan, Blanca Gonzalez-Farre, Thomas Heineman, Gerard Nuovo, Grey Wilkinson, Matt Coffey, Azucena Gonzalez, Débora Martínez, Laia Paré, Fernando Salvador, Xavier Gonzalez, Aleix Prat, Joaquín Gavilá

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A482; DOI: 10.1136/jitc-2020-SITC2020.0806
808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)
Osama Rahma, Joanna Baginska, Martha Brainard, Anita Giobbie-Hurder, Kevin Tyan, James Cleary, Benjamin Schlechter, Anna Maloney, Michael Manos, Rizwan Romee, Mariano Severgnini, F Stephen Hodi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A483-A484; DOI: 10.1136/jitc-2020-SITC2020.0808
809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival
Trisha Wise-Draper, Shuchi Gulati, Vinita Takiar, Sarah Palackdharry, Francis Worden, Matthew Old, John Kaczmar, Neal Dunlap, Benjamin Hinrichs, Diana Bell, Yash Patil, Muhammad Kashif Riaz, Layne Weatherford, Aubrey Hamilton, Sheena Lanverman, Michelle Mierzwa, Keith Casper, Jonathan Mark, Alice Tang, Chad Zender, Ann Gillenwater, Mario Medvedovich, J Jack Lee, Roman Jandarov, Maura Gillison

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A484-A485; DOI: 10.1136/jitc-2020-SITC2020.0809
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
Lei Zheng, Carol Judkins, Jessica Hoare, Rachel Klein, Rose Parkinson, Hao Wang, Haihui Cao, Jennifer Durham, Katrina Purtell, Ana De Jesus-Acosta, Dung Le, Amol Narang, Robert Anders, Richard Burkhart, William Burns, Christopher Wolfgang, Elizabeth Thompson, Daniel Laheru, Jin He, Elizabeth Jaffee

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A486-A487; DOI: 10.1136/jitc-2020-SITC2020.0812
817 DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties
Anne-Laure Blayo, Laurène Deshons, Alexia Dumont, Christel Franchet, Célia Halter, Ludovic Herbin, Gaël Hommet, Stanislas Mayer, Alban Bessede, Imane Nafia, Marjorie Sidhoum, Xavier Leroy, Stéphan Schann

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A488; DOI: 10.1136/jitc-2020-SITC2020.0817
79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Jianming Xu, Nong Xu, Yuxian Bai, Chia-Chi Lin, Michael Millward, Jingwen Shi, Yun Zhang, Xiaopeng Ma, Zhirong Shen, Ruiqi Huang, Wei Huang, Lin Shen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A49; DOI: 10.1136/jitc-2020-SITC2020.0079
9 Mesenchymal features of a novel 27-gene algorithm associate with canonical tumor promoting signaling pathways which may identify therapeutic options for immunotherapy resistant patients
Tyler Nielsen, Rob Seitz, Douglas Ross, David Hout, Brock Schweitzer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A5-A6; DOI: 10.1136/jitc-2020-SITC2020.0009
81 Inclusion of PD-L1-expressing tumor cells in the combined positive score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications
Jay Milo, Christopher LaPlaca, Julia Hand, Stephanie Hund, Angeliki Apostolaki, Lindsay Guerrero, Kenneth Emancipator, Jonathan Juco, Bryce Portier, Siena Tabuena-Frolli, Karina Kulangara

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A50-A51; DOI: 10.1136/jitc-2020-SITC2020.0081
84 Quantifying pharmacodynamic biomarker changes in immuno-oncology by mass spectrometry
Joseph Eckenrode, Omar Laterza, Michael Lassman

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A53-A54; DOI: 10.1136/jitc-2020-SITC2020.0084

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages